This inventor holds 3 USPTO granted patents. Top assignee: Cayman Chemical Company Incorporated. Active years: 2008-2010.
Company Filing History:
Years Active: 2008-2010
Title: Michelle L Stanton: Innovator in Ophthalmic Solutions
Introduction
Michelle L Stanton is a prominent inventor based in Ann Arbor, MI (US). She has made significant contributions to the field of ophthalmology through her innovative work on prostaglandin compounds. With a total of 3 patents, her research focuses on developing effective treatments for conditions such as glaucoma.
Latest Patents
Stanton's latest patents include novel derivatives of prostaglandin compounds of the F-series (PGF). Specifically, she has worked on macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol and latanoprost. These novel analogs can be formulated into ophthalmic solutions and are designed for topical application to treat increased intraocular pressure caused by glaucoma and to reduce ocular hypertension.
Career Highlights
Throughout her career, Stanton has been associated with Cayman Chemical Company Incorporated, where she has furthered her research and development efforts. Her work has been instrumental in advancing the understanding and treatment of ocular conditions.
Collaborations
Stanton collaborates with various professionals in her field, including her coworker Kirk M Maxey. Their combined expertise contributes to the innovative solutions being developed at Cayman Chemical Company.
Conclusion
Michelle L Stanton's contributions to ophthalmic solutions highlight her dedication to improving patient care in the field of ophthalmology. Her innovative patents and collaborative efforts continue to pave the way for advancements in treating glaucoma and ocular hypertension.